REGN Q3 2026 Earnings Analysis
Q3 revenue reached $5.1B (+36%) with EPS growth of 70%, driven by record sales of Dupixent, EYLEA HD, and Libtayo; $1B Sanofi deal expanded alliance for 4 next-gen antibodies.
Key Metrics
Key Takeaways
- Record Q3 revenue $5.1B (+36% YoY): Dupixent $6.5B (+35%), EYLEA HD +62%, Libtayo +51% all-time highs.
- $1B Sanofi upfront for 4 next-gen antibodies; alliance restructured for 50/50 profit-sharing.
- Pipeline advances: cemdisiran FDA decision November; CIDEB shows 70% liver fat reduction; ubamatamab 70% cancer response.
Listen On
Available In
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown, where we turn dense earnings calls into conversations you'd actually want to have with a friend. I'm Alex.
And I'm Jordan. Alex, we've got a big one today.
We really do — Regeneron, ticker REGN, reporting Q3 2026 results. But before we jump in, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Important stuff. Okay, so Alex, let's set the scene — the stock popped nearly 13% on this print. That's not a small move for a company this size.
No kidding. And when you look at the numbers, it's easy to see why. Total revenue grew 36% year-over-year to $5.1 billion. Non-GAAP earnings per share jumped 70% to $20.07. This is the third straight quarter of double-digit growth on both the top and bottom line.
And it wasn't just one product carrying the load. Dupixent, EYLEA HD, and Libtayo — their three biggest commercial brands — each hit all-time-high quarterly sales. Two quarters in a row, actually.
Let's break those down one at a time, because the Dupixent number alone is wild. Global sales hit $6.5 billion, up 35% at constant currency. In the U.S. specifically, sales crossed $5 billion for the first time ever.
For a drug that's approaching its tenth year on the market, that's genuinely remarkable. Most blockbuster drugs plateau or start fading by year ten — Dupixent is accelerating. It's the leading biologic in eight of its nine approved indications.
Then there's EYLEA HD, the next-gen eye medicine. U.S. sales hit $699 million, up 62% year-over-year, and it now makes up almost two-thirds of their retinal franchise. Physician demand grew 20% sequentially.
Though I'll note — the older EYLEA formulation is declining fast, down 41%, as biosimilar competition eats into that market. So this is really a story of EYLEA HD cannibalizing its predecessor successfully, which is the right problem to have.
Right, it's a managed transition, not just pure growth. And then Libtayo, their cancer immunotherapy — $550 million globally, up 51%. It's now running at an annual pace of about $2.2 billion.
Now here's the part that I think got Wall Street really excited — the Sanofi relationship. Regeneron finished repaying its development cost balance to Sanofi, which means for the first time, they're collecting their FULL share of Dupixent collaboration profits. No more clawbacks eating into the number.
And on top of that, they announced an expanded alliance — four next-generation long-acting antibodies targeting the same pathways that made Dupixent a hit. Regeneron gets a $1 billion upfront payment landing in Q4, and going forward, they split both R&D costs and profits 50/50 with Sanofi. That's a much better deal structurally than before.
CEO Leonard Schleifer called it leading "the next era of type 2 inflammation medicines." And CSO George Yancopoulos made an interesting point in the Q&A — he argued their antibodies are "naturally derived" from their humanized mouse platform, versus competitors using heavily engineered older antibodies, which historically have more immune and safety issues.
That's classic Regeneron — leaning on their genetics-driven science story. Speaking of which, the CIDEB program in NASH, or fatty liver disease, might be the most eye-popping pipeline data point this quarter.
Yeah, this one's worth pausing on. Regeneron's genetics database found people with a naturally occurring loss-of-function in the CIDEB gene have dramatically lower rates of fatty liver disease. So they built an siRNA drug targeting it — and in early trials, a single dose cut liver fat by about 70% in just 12 weeks, with effects lasting through 24 weeks.
George Yancopoulos called it "unprecedented" and said it directly addresses the genetic root cause rather than working indirectly like GLP-1 drugs do. They're fast-tracking this into registration studies now.
Also notable: ubamatamab, their bispecific antibody for a rare ovarian cancer, showed roughly a 70% response rate — compare that to under 15% for chemo, historically. And cemdisiran, their siRNA drug for myasthenia gravis, has an FDA decision expected in November. If approved, it'd be the first siRNA therapy ever for that disease.
Let's talk financials and guidance, because Christopher Fenimore, the CFO, had some useful color. Free cash flow hit $2.9 billion through nine months. They've got $16.2 billion in cash and securities net of debt. And they've been aggressive on buybacks — about $2.3 billion repurchased this year, with roughly $3 billion expected for the full year.
On the expense side, they're guiding 2027 R&D spend up by a mid-teens percentage, which signals real confidence in the pipeline — nearly 15 Phase 3 trials are either running or starting soon across myeloma, blood clot prevention, and obesity.
One thing analysts pressed on was business development — would Regeneron get more aggressive buying outside assets? Schleifer's answer was basically "we're open to anything, but our internal pipeline keeps outperforming what we'd buy externally."
Which, frankly, tracks given what we just covered. When your own genetics engine is producing drugs like CIDEB and the POTS program — Regeneron also flagged promising early data for a potential first-ever FDA-approved treatment for POTS, that debilitating heart-rate disorder — it's hard to argue they need to go shopping.
So pulling this together — what's the real takeaway for investors here?
I'd frame it as three things: one, the core commercial engine — Dupixent, EYLEA HD, Libtayo — is firing on all cylinders with real, durable growth, not just one-time boosts. Two, the restructured Sanofi deal materially improves Regeneron's economics going forward, immediately and durably. And three, the pipeline depth — NASH, oncology, neurology, rare disease — gives this company multiple shots at future blockbusters rather than depending on one drug.
That diversification point matters too — they're now active across nearly every medical specialty, which gives them infrastructure advantages when new drugs launch.
Before we wrap — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Well said. Looking ahead, keep an eye on that November FDA decision for cemdisiran, the November 10th Next-Generation Roundtable where they'll detail more CIDEB data, and how the Sanofi antibody pipeline develops through 2027.
Lots of catalysts stacked up back-to-back. This is a name to keep watching closely.
Couldn't agree more. That's it for this episode of Beta Finch — thanks for listening, and we'll catch you next time.
See you then!